乙肝后肝硬化失代偿期患者抗病毒治疗的疗效与经济学研究

目的：对乙肝后肝硬化失代偿期患者分别采用抗病毒治疗和一般护肝治疗，观察两组患者的临床疗效及经济学效益差异。方法选择我院接诊的155例乙肝后肝硬化失代偿期患者，其中98例患者采用抗病毒治疗（实验组），57例患者仅采用一般护肝治疗（对照组）。疗程结束后，观察两组患者的临床疗效，同时进行经济成本与效果分析。结果实验组患者死亡5例，对照组患者死亡18例，占总死亡率的78.2%。且临床疗效实验组患者明显优于对照（P＜0.05）；经济成本与效果分析，实验组患者经济成本明显低于对照组（P＜0.05）。结论采用抗病毒药物治疗乙肝后肝硬化失代偿期患者疗效好、费用低，是治疗乙肝后肝硬化失代偿期患者的重要治疗手段。

Study of efficacy and economics of antiviral treatment of decompensated liver cirrhosis following hepatitis B

Objective To observe the differences in clinical efficacy and economic benefits between the two groups of patients with decompensated liver cirrhosis following hepatitis B who received antiviral treatment and ordinary liver protection treatment respectively. Methods 155 patients with decompensated liver cirrhosis following hepatitis B who were admitted to our hospital were selected, of which 98 patients received antiviral treatment（experimental group） and 57 patients only received ordinary liver protection treatment（control group）. After treatment, clinical efficacy of the two groups was observed and meanwhile their economic costs and effects were analyzed. Results Five patients died in the experimental group and 18 patients died in the control group, accounting for 78.2%of the total death rate. The experimental group had significantly better clinical efficacy than the control group（P 〈 0.05）; In terms of economic cost and effect analysis, the experimental group had significantly lower economic cost than the control group（P〈0.05）. Conclusion In the treatment of decompensated liver cirrhosis following hepatitis B, antiviral drug treatment has good efficacy and low cost, which is an important treatment method for the patients with decompensated liver cirrhosis following hepatitis B.